Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Louise Carter"'
Autor:
Chelsea S. Sawyer, Sally Taylor, Louise Carter, Melissa Stanworth, Michelle Davies, Fiona Thistlethwaite, Jo Taylor, Charlotte Eastwood, Janelle Yorke
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Our aim was to develop a validated Patient Reported Experience Measure (PREM) to capture patient and carer experience during participation in experimental cancer medicine trials (ECM): called PREM-ECM. Methods Mixed method design,
Externí odkaz:
https://doaj.org/article/ba449acd2ee04567936770f30e75b5d8
Autor:
Lydia Sutherland, Louise Carter
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e32597- (2024)
Sex is an essential biological variable that influences the development, progression and response to treatment in cancer. Despite this, early-phase cancer clinical trials frequently neglect to consider sex as a variable, creating a barrier to the dev
Externí odkaz:
https://doaj.org/article/6c8f351d7dcd41ddbac710f180f00d4b
Autor:
Janelle Yorke, Laurie Preston, Natalie Cook, Sally Taylor, Michelle Davies, Matthew Krebs, Louise Carter, Chelsea Sawyer, Donna Graham, Fiona Thistlewaite
Publikováno v:
BMJ Open, Vol 11, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/3e80f2c8c7d84bbeba3cfb10c9c944ee
Autor:
Barbara Mesquita, Dominic G. Rothwell, Deborah J Burt, Francesca Chemi, Fabiola Fernandez‐Gutierrez, Daniel Slane‐Tan, Jenny Antonello, Mathew Carter, Louise Carter, Marina Parry, Lynsey Franklin, Richard Marais, Fiona Blackhall, Caroline Dive, Ged Brady
Publikováno v:
Molecular Oncology, Vol 11, Iss 12, Pp 1687-1697 (2017)
The CellSearch® semiautomated CTC enrichment and staining system has been established as the ‘gold standard’ for CTC enumeration with CellSearch® CTC counts recognized by the FDA as prognostic for a number of cancers. We and others have gone on
Externí odkaz:
https://doaj.org/article/dc5ac6e5a257460b922feefcdabcc978
Autor:
Bethany Geary, Erin Peat, Sarah Dransfield, Natalie Cook, Fiona Thistlethwaite, Donna Graham, Louise Carter, Andrew Hughes, Matthew G. Krebs, Anthony D. Whetton
Publikováno v:
Cancers, Vol 13, Iss 10, p 2443 (2021)
TARGET (tumour characterisation to guide experimental targeted therapy) is a cancer precision medicine programme focused on molecular characterisation of patients entering early phase clinical trials. Performance status (PS) measures a patient’s ab
Externí odkaz:
https://doaj.org/article/5cad531234ad4c29bb060083fc08b465
Publikováno v:
Cells, Vol 9, Iss 12, p 2586 (2020)
Small cell lung cancer (SCLC) has a particularly poor prognosis despite the high initial response to first-line systemic therapy, and there is a well-recognised lack of meaningful treatments beyond the second line. A number of reasons have been put f
Externí odkaz:
https://doaj.org/article/a110e20b78d94dc18c84079c29f27cf1
Autor:
Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Publikováno v:
Scientia
Gemcitabina; Cáncer avanzado Gemcitabina; Càncer avançat Gemcitabine; Advanced cancer Purpose: This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to estab
Publikováno v:
Orthodontic Update. 15:199-205
The objective of this study was to assess the feasibility and acceptability of conducting remote new patient consultations using teleorthodontics. Part 1 of the study used a five-point Likert-scale patient questionnaire and Part 2 comprised an orthod
Autor:
Amy Louise Carter
Publikováno v:
Dams and Reservoirs. 32:95-100
The UK dams and reservoirs community is experiencing renewed public attention following the Toddbrook incident of 2019, among several other recent global incidents. In light of this, many undertakers are now seeking to limit their liabilities through
Autor:
Rebecca Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah Blagden, Debashis Sarker, Tobias Arkenau, Thomas R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Publikováno v:
British Journal of Cancer.
Background This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737. Methods Patients with advanced solid tumours enrolled in dose-escalation cohorts and received SRA737 monotherapy